123447-62-1; NM441; NM 441; NM-441; Prulifloxacin (hydrochloride); 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; NCGC00164615-01; Quisnon; DSSTox_CID_26480; DSSTox_RID_81651; DSSTox_GSID_46480; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-; 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; Prulifloxacin [INN]; Pruvel; Sword; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; CCRIS 7686; CAS-123447-62-1; Pufloxacin dioxolil; 6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; MLS006011767; CHEMBL422648; NAD-441A; OPT-99; SCHEMBL1650794; DTXSID0046480; CHEBI:32071; AOB5600; BCP12727; HY-B0024; Tox21_112235; BBL034010; MFCD00864847; s2071; STK626148; AKOS005559236; Prulifloxacin (NM441, AF 3013); Tox21_112235_1; AC-2012; DB11892; MCULE-8435182996; SB18983; NCGC00164615-02; NCGC00164615-03; (+-)-7-(4-((Z)-2,3-Dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, cyclic carbonate; AK144730; AS-13607; I926; SMR000046722; AB0013936; FT-0651733; P2058; Prulifloxacin 100 microg/mL in Acetonitrile; K-1771; 447P621; Prulifloxacin, >=98% (perchloric acid titration); SR-01000872596; Prulifloxacin, Antibiotic for Culture Media Use Only; Q-101929; Q3924793; SR-01000872596-1; BRD-A92341659-001-01-6